Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Diltiazem drug class?Defense strategy against generic in niche market?Abbvie humira patent cliff navigation success?What's the advised delay for milk post lipitor?Drugpatentwatch skyrizi biologic patent analysis?
See the DrugPatentWatch profile for xgeva
Where can I buy Xgeva? Xgeva is a prescription medication that requires a valid doctor's order. You can obtain it through hospital outpatient departments, oncology clinics, or any pharmacy that carries special-order biologics. Most patients receive the injection directly at their doctor's office or clinic. Can Xgeva be filled at retail pharmacies? Most retail pharmacies do not keep Xgeva in stock. Patients usually receive the drug during their scheduled medical appointments. Some hospital pharmacies or specialty pharmacies may accept prescriptions for home delivery after receiving a physician's order. How does Xgeva compare with Zometa? Xgeva contains denosumab, a monoclonal antibody, while Zometa contains zoledronic acid, a bisphosphonate. Xgeva requires subcutaneous injection once every four weeks. Zometa requires intravenous infusion every three to four weeks. Xgeva has a risk of hypocalcemia and jaw osteonecrosis but requires no renal dose adjustments. Zometa needs kidney-function monitoring. When does Xgeva's patent expire? Xgeva's primary patent for denosumab expired in 2020. Biosimilar versions are now in development or under review by the FDA. [1] Why are companies challenging this patent? Biosimilar developers challenge patents to accelerate market entry. Companies such as Sandoz and Amgen have ongoing litigation over denosumab formulations. The disputes focus on manufacturing methods and formulation patents that extend exclusivity beyond 2020. [1] Can biosimilars enter before patent expiry? Biosimilars cannot enter the market legally before core patents expire or are invalidated. Current litigation may further delay launches. Biosimilars of denosumab will likely appear first in Europe and then in the United States. [1] Where is Xgeva made? Xgeva is produced by Amgen at its facilities in Thousand Oaks, California, and Joure, Netherlands. The company also maintains production sites in Puerto Rico for biologics.
Other Questions About Xgeva :